GSK, Teva See Bigger Issues Than Cash In $235M Award Fight
Attorneys for GlaxoSmithKline and Teva Pharmaceuticals both told a Delaware federal judge on Thursday that far more than money is at stake in post-trial challenges to a $235 million heart drug...To view the full article, register now.
Already a subscriber? Click here to view full article